West Pharmaceutical Services (WST) Non-Current Assets (2009 - 2026)

West Pharmaceutical Services has disclosed Non-Current Assets across 18 years of filings, most recently posting $2.3 billion for Q2 2026.

• In Q2 2026, Non-Current Assets changed 0.13% year-over-year to $2.3 billion; the TTM figure through Jun 2026 stood at $9.1 billion (up 5.35% YoY), while the FY2025 annual figure was $2.3 billion, up 8.86% from the prior year.
• Non-Current Assets came in at $2.3 billion for Q2 2026 at West Pharmaceutical Services, down from $2.3 billion in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $2.3 billion in Q4 2025 to a low of $1.6 billion in Q3 2022.
• Average Non-Current Assets over 5 years is $2.0 billion, with a median of $2.0 billion recorded in 2024.
• Year-over-year, Non-Current Assets increased 19.19% in 2024 and decreased 0.13% in 2026.
• Over 5 years, Non-Current Assets stood at $1.7 billion in 2022, then advanced by 11.54% to $1.9 billion in 2023, then advanced by 11.21% to $2.1 billion in 2024, then advanced by 8.86% to $2.3 billion in 2025, then fell by 1.0% to $2.3 billion in 2026.
• Per Business Quant data, the three most recent Non-Current Assets figures were $2.3 billion in Q2 2026, $2.3 billion in Q1 2026, and $2.3 billion in Q4 2025.